8-K: Aspire Biopharma Holdings Relocates Principal Executive Office to Estero, Florida
Current Report (8-K)
Aspire Biopharma Holdings, Inc. announced on June 17, 2025, the relocation of its principal executive office, principal place of business, and headquarters to Estero, Florida.
Summary
- Aspire Biopharma Holdings, Inc. (the "Company") changed its principal executive office on June 17, 2025.
- The new principal executive office, principal place of business, and headquarters is located at 23150 Fashion Drive, Suite 232, Estero, Florida 33928.
- The Company's former address was 194 Candelaro Drive, #233, Humacao, Puerto Rico 00791.
- The change was approved by the Company's Board of Directors.
- Aspire Biopharma Holdings, Inc. is listed on The Nasdaq Stock Market LLC under the trading symbols ASBP for common stock and ASBPW for warrants.
Sentiment
Score: 5
Explanation: The document reports a neutral, administrative change of the company's principal executive office. There are no positive or negative implications for financial performance or strategic direction mentioned.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding future financial performance or strategic direction beyond the administrative change of address.
Industry Context
This administrative change of principal executive office is an internal corporate matter and does not directly relate to broader industry trends or competitive dynamics within the biopharma sector. It is a routine disclosure for publicly traded companies when such a change occurs.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Principal Executive Office Relocation | The Board of Directors approved the change of the Company's principal executive office, principal place of business, and headquarters from Humacao, Puerto Rico to Estero, Florida. | 2025-06-17 | This is an administrative change with no stated impact on corporate governance structure, bylaws, or operational policies beyond the physical location of the main office. |
Stakeholder Impact
- Shareholders: Minimal direct impact, as this is an administrative change of address and does not affect company operations or financial performance.
- Employees: Potential impact on employees currently working at the former Puerto Rico location, requiring relocation or changes in work arrangements, though no specific details are provided.
- Customers/Suppliers: No direct impact on customer or supplier relationships is indicated by a change in the principal executive office.
Key Dates
| Date | Description |
|---|---|
| 2025-06-17 | Date the Board of Directors changed the Company's principal executive office. |
| 2025-06-18 | Date the Form 8-K report was signed by the Chief Financial Officer. |
Keywords
Aspire Biopharma Holdings, ASBP, SEC filing, 8-K, corporate relocation, headquarters change, Estero Florida, biopharma
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.